Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Control (AC) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

NCT07020988
View directory record Official record
Conditions
Healthy Participants
Interventions
Staccato Alprazolam, Midazolam, Diazepam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
20 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Recruiting Phase 2 Interventional

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

NCT06504459
View directory record Official record
Conditions
Acute Monocytic Leukemia, Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cladribine, Cytarabine, Echocardiography, Lumbar Puncture, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Miami, Florida • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

NCT05140096
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Fluconazole, Isavuconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 25, 2026, 5:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Optimizing a Technology-based Body and Mind Intervention

NCT05778604
View directory record Official record
Conditions
Fall, Fear of Falling, Physical Inactivity, Sedentary Behavior
Interventions
Physio-feedback, Cognitive reframing, Peer-led exercises, CDC older adults fall prevention
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
60 Years and older
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Not applicable Interventional

Telehealth Based Intervention to Improve Functional Capacity in Survivors of Childhood Cancer With Significantly Limited Exercise Tolerance

NCT04714840
View directory record Official record
Conditions
Childhood Cancer, Mobility Limitation
Interventions
Exercise testing results, Individually tailored exercise program (INT), Generalized exercise recommendations (AC)
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 39 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Not applicable Interventional Results available

Respiratory Exacerbation Plans for Action and Care Transitions for Children With Severe CP

NCT05292365
View directory record Official record
Conditions
Cerebral Palsy
Interventions
RE-PACT Intervention
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 25, 2026, 5:55 PM EDT
Suspended Phase 1 Interventional

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

NCT06888323
View directory record Official record
Conditions
Refractory Myelodysplastic Syndrome
Interventions
Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab, Computed Tomography, Single Photon Emission Computed Tomography
Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Recruiting Not applicable Interventional

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

NCT06411561
View directory record Official record
Conditions
Critical Illness, Delirium, Cognitive Impairment, Cognitive Decline, Alzheimer's Disease, Dementia, Circadian Dysrhythmia, Sleep Disturbance
Interventions
SLEEP + COG, COG, SLEEP, AC
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

NCT00097786
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 99 Years
Enrollment
9,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 25, 2026, 5:55 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

NCT04373031
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Pembrolizumab, IRX 2
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Not applicable Interventional Results available

Staying Positive With Arthritis Study

NCT02223858
View directory record Official record
Conditions
Arthritis
Interventions
Positive Activities (PA) Program, Attention Control (AC) Program
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 25, 2026, 5:55 PM EDT
Recruiting Phase 3 Interventional

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

NCT05834478
View directory record Official record
Conditions
Withdrawal Symptoms, Opioid Use Disorder, Opioid Use
Interventions
Transcutaneous Cervical Vagal Nerve Stimulation, Sham Stimulation, [F-18]Fallypride
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Not applicable Interventional

Frontoparietal Synchronization to Modulate Drug Craving in Opioid Use Disorder

NCT03907644
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Transcranial Alternating Current Stimulation (tACS)
Device
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 61 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Phase 3 Interventional

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT00389779
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
87
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 25, 2026, 5:55 PM EDT
Enrolling by invitation Not applicable Interventional

SHADES Mechanistic Trial

NCT06041581
View directory record Official record
Conditions
Insomnia, Insomnia Chronic, Insomnia, Primary, Sleep Disturbance, Sleep Disorder, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke, Autonomic Dysfunction, Systemic Inflammatory Response, Metabolic Disease
Interventions
Sleep Healthy Using The Internet (SHUTi), Telephonic CBT-I, Face-to-Face CBT-I, Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care
Behavioral · Other
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Not yet recruiting Not applicable Interventional

Patient-Oriented Research to Optimize Cochlear Implant Outcomes

NCT07678879
View directory record Official record
Conditions
Cochlear Implant, Cochlear Implant Users, Cochlear Implant Recipients, Cochlear Implant Listeners
Interventions
AC Group, CA group
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Obesity Intervention for Low-Income African American Preschoolers

NCT02456623
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Intervention, Attention Control
Behavioral
Lead sponsor
Eastern Michigan University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 25, 2026, 5:55 PM EDT
Recruiting Not applicable Interventional

Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial

NCT05356117
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Resistance Training (RT) and Protein Supplementation (PS), Resistance Training (RT), Attention Control (AC
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Enrolling by invitation Not applicable Interventional

Experimental Trial of an Employment-Based Housing Program for Adults at Risk of Homelessness

NCT07470372
View directory record Official record
Conditions
Emergency Department Visits, Housing Stability, Employment, Sleep Quality, Health-Related Quality-of-Life
Interventions
Employment-Based Housing, Vocational Services, Resources
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Completed Not applicable Interventional

Computerized Alcohol Misuse Intervention System for Health Care

NCT02368899
View directory record Official record
Conditions
Alcoholism
Interventions
Computerized Alcohol Misuse Intervention, Attention Control (AC)
Other
Lead sponsor
Research Circle Associates, LLC
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 25, 2026, 5:55 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Reducing Firearm Suicide Among Veterans: Evaluating the Effectiveness of Peer-Delivered Lethal Means Counseling

NCT07033884
View directory record Official record
Conditions
Suicide, Secure Firearm Storage
Interventions
Peer Engagement and Exploration of Responsibility and Safety, Active Control
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 25, 2026, 5:55 PM EDT
Recruiting Not applicable Interventional

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

NCT06123988
View directory record Official record
Conditions
HER2-positive Breast Cancer, Advanced Breast Cancer
Interventions
Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Phoenix, Arizona • Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 5:55 PM EDT